ArticleTransplantation and cellular therapy2026
Fear of Cancer Recurrence in Hematopoietic Cell Transplantation Survivors.
Article in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Fear of cancer recurrence (FCR) is a significant challenge faced by hematopoietic cell transplantation (HCT) survivors, yet it remains insufficiently characterized in this group, limiting the ability to develop interventions to reduce FCR. We aimed to determine the prevalence and correlates of clinically significant levels of FCR (csFCR) in a large cohort of long-term HCT survivors at a major cancer center. From July 1, 2023 through June 30, 2024, survivors who underwent HCT >1 year ago at Fred Hutch Cancer Center received an annual patient recovery questionnaire (PRQ) and FCR module that included Patient-Reported Outcomes Measurement Information System (PROMIS) instruments, the FCR Inventory-Short Form (FCRI-SF), and questions regarding adherence to healthcare maintenance and cancer screening. csFCR was defined as a score ≥16 on the FCRI-SF. We determined predictors of csFCR using logistic regression and compared PROs, healthcare maintenance, and cancer screening by presence of csFCR. Of 4514 participants, 1501 (33%) completed the PRQ and FCR module, and 513 (34%) reported csFCR. In univariate logistic regression, younger age at survey completion, shorter time from HCT, diagnosis, intermediate or high pre-HCT disease risk, current receipt of maintenance therapy, and history of post-HCT relapse were significantly associated with higher odds of csFCR. In multivariable logistic regression, younger age at survey completion, shorter time from HCT, and history of post-HCT relapse remained independently associated with higher odds of csFCR. Survivors with csFCR reported lower PROMIS physical and psychosocial function, greater anxiety before hematology/oncology appointments, and greater need for, yet reduced access to, psychological care. Rates of cancer screening did not differ significantly by presence of csFCR. HCT survivorship programs should integrate psychosocial support to address FCR and determine whether targeted interventions can mitigate FCR and improve quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.